Kurs kaydını izlemek için tıklayınız.

• 2. Modül Programı
• 2021 ELN Update on AML MRD
• A concise review on the molecular genetics of acute myeloid leukemia
• ACS AML Page
• Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML)
• Driver mutations in acute myeloid leukemia
• inimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
• Expanding WHO Classfication
• Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers
• Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes
• HOVON_SAKK AML 42A Study
• Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations
• Minimal_Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry
• Morphology, IP and genetic in AML cases Bain & Bene
• MRD
• Persistence of Minimal Residual Disease Assessed by Multi- Parameter Flow Cytometry is Highly Prognostic in Younger Patients with Acute Myeloid Leukemia
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
• Measurable residual disease monitoring in acute myeloid leukeima with t(8;21)(q22;q22.1): results from the AML Study Group